Clinicopathologic spectrum of myeloid neoplasms with concurrent myeloproliferative neoplasm driver mutations and SRSF2 mutations.

doi:10.1038/s41379-022-01118-3

Loading publication...

Noodle always counts identifier-free feature events for service operation. With your permission, Google Analytics can also estimate audience and engagement. Search text, publication identifiers, cookies, IP addresses and browser fingerprints are never included in Noodle's first-party event counters.

Privacy details

Community

Back to search

Article

Clinicopathologic spectrum of myeloid neoplasms with concurrent myeloproliferative neoplasm driver mutations and SRSF2 mutations.

Modern pathology : an official journal of the United States and Canadian Academy of Pathology, Inc - 1 Nov 2022

Tashakori Mehrnoosh, Khoury Joseph D, Routbort Mark J, Patel Keyur P, Wang Sa A, Ok Chi Young, El-Hussein Siba, Kanagal-Shamanna Rashmi, Luthra Rajyalakshmi, Hu Shimin, Lin Pei, Pemmaraju Naveen, Bose Prithviraj, Verstovsek Srdan, Bueso-Ramos Carlos E, Medeiros L Jeffrey, Loghavi Sanam

Abstract excerpt

Myeloproliferative neoplasms (MPNs) are frequently associated with classic driver mutations involving JAK2, MPL or CALR. SRSF2 is among the most frequently mutated splicing genes in myeloid neoplasms and SRSF2 mutations are known to confer a poor prognosis in patients with MPNs. In this study, we sought to evaluate the clinicopathologic spectrum of myeloid neoplasms harboring concurrent MPN-driver mutations and...

Read the complete abstract on PubMed

Topics

Share this publication in a Topic to start or enrich a Post.

Share to Aged

Methodology Data sources Editorial policy Privacy About Contact Helena Bioinformatics

Share to Aged, 80 and over

Share to Janus Kinase 2

Share to Myeloproliferative Disorders

Share to Neoplasms

Share to Primary Myelofibrosis

Share to RNA-Binding Proteins

Share to Serine-Arginine Splicing Factors

Source

Open in PubMed

Identifiers

PMID: 35690645
DOI: 10.1038/s41379-022-01118-3

Provenance

PubMed metadata and Literature Corpus relationships. Corpus snapshot updated 2 Sept 2026.

Related research

Semantic proximity does not establish scientific evidence.

Research trail→

Click a neighbor to travelStep 1 · 12 closest

Clinicopathologic spectrum of myeloid neoplasms with concurrent myeloproliferative neoplasm driver mutations and SRSF2 mutations.PMID 35690645Read ↗

Co-occurring mutations in ASXL1, SRSF2, and SETBP1 define a subset of myelodysplastic/ myeloproliferative neoplasm with neutrophilia.Semantic proximity Read ↗

Surveying the landscape of MDS/MPN research: overlap among the overlap syndromes?Semantic proximity Read ↗

Co-mutation pattern, clonal hierarchy, and clone size concur to determine disease phenotype of SRSF2P95-mutated neoplasms.Semantic proximity Read ↗

Clinicopathologic characterisation of myeloid neoplasms with concurrent spliceosome mutations and myeloproliferative-neoplasm-associated mutations.Semantic proximity Read ↗

Chronic myeloid neoplasms harboring concomitant mutations in myeloproliferative neoplasm driver genes (JAK2/MPL/CALR) and SF3B1.Semantic proximity Read ↗

Exploring the Molecular Landscape of Myelofibrosis, with a Focus on Ras and Mitogen-Activated Protein (MAP) Kinase SignalingSemantic proximity Read ↗

Triple-Negative Primary Myelofibrosis: A Bone Marrow Pathology Group Study.Semantic proximity Read ↗

Genetic-pathologic characterization of myeloproliferative neoplasms.Semantic proximity Read ↗

Myeloid neoplasms with features intermediate between primary myelofibrosis and chronic myelomonocytic leukemia.Semantic proximity Read ↗

Driver mutations in primary myelofibrosis and their implications.Semantic proximity Read ↗

Many faces of SF3B1-mutated myeloid neoplasms: concurrent mutational profiles contribute to the diverse clinical and morphologic features.Semantic proximity Read ↗

The detection of SRSF2 mutations in routinely processed bone marrow biopsies is useful in the diagnosis of chronic myelomonocytic leukemia.Semantic proximity Read ↗

⌁Select a neighboring publication to make it the new centre.